From: Societal preferences for adjuvant melanoma health states: UK and Australia
Know someone with melanoma (n = 28) | Do not know someone with melanoma (n = 122) | p value | |
---|---|---|---|
Current health | 0.989 ± 0.04 | 0.978 ± 0.08 | 0.507 |
Adjuvant treatment no toxicities | 0.952 ± 0.09 | 0.877 ± 0.16 | 0.001 |
Induction treatment | 0.941 ± 0.08 | 0.865 ± 0.17 | 0.001 |
No treatment | 0.895 ± 0.16 | 0.846 ± 0.20 | 0.222 |
Fatigue | 0.896 ± 0.13 | 0.821 ± 0.18 | 0.019 |
Nausea | 0.873 ± 0.15 | 0.800 ± 0.20 | 0.078 |
Rash | 0.885 ± 0.16 | 0.800 ± 0.20 | 0.040 |
Flu | 0.853 ± 0.17 | 0.805 ± 0.18 | 0.195 |
Diarrhea | 0.851 ± 0.19 | 0.785 ± 0.21 | 0.127 |
Toxicity-outpatient | 0.886 ± 0.14 | 0.764 ± 0.21 | 0.001 |
Depression | 0.831 ± 0.22 | 0.768 ± 0.23 | 0.154 |
Hypophysitis | 0.818 ± 0.17 | 0.742 ± 0.21 | 0.078 |
Long-term survival | 0.843 ± 0.19 | 0.715 ± 0.22 | 0.003 |
Toxicity-hospital | 0.791 ± 0.18 | 0.726 ± 0.21 | 0.133 |
Recurrence of cancer | 0.673 ± 0.26 | 0.607 ± 0.25 | 0.215 |